Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

  • p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i3Z|AuOTBizszN NV24e|Y2OC12IHS= M4jmO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYjzbIo{OjZ5MEK3PFQ>
HepG2 M4KxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXjUGZzOC1zMDFOwG0> MY[wMVQh\A>? NHL3eYJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2LkcVI3PzB{N{i0
HT29 MYDGeY5kfGmxbjDBd5NigQ>? NG\0RZY2OMLibl2= MnzZNlQuPzJiaB?= Mmn6bY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg NIH2WZMzPjdyMke4OC=>
HepG2 Ml\zSpVv[3Srb36gRZN{[Xl? MVi1NOKhdk1? M1qwSlI1NTd{IHi= NUGyWHNOcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh NGrTVZIzPjdyMke4OC=>
HCC827 M122emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu1M|cvPS9zMDDuUS=> M2XadFczyqCq NWjaZlNSTE2VTx?= NULid4V6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MXqyOlY4PTR6NB?=
A549  NFz2VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\DNVAwOTVxMkCgcm0> MmntO|LDqGh? MUDEUXNQ MXrlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MYqyOlY4PTR6NB?=
NCI-H460  MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWflUolKOTBxMkCvN|Ahdk1? MUC3NuKhcA>? MVLEUXNQ MlXw[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NF7LNFMzPjZ5NUS4OC=>
J89GFP NE\vWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTPW2NFVVORwrC= NWm1OYU6TUN3ME20PU45PSEEsTCxNk43PSCwTR?= MmLnNlY2PjN3Nki=
THP89GFP NFXtSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;5Z2ROW00EoB?= NWjS[W94TUN3ME2xPU4{PCEEsTC2MlQ{KG6P M2PldVI3PTZ|NU[4
SK-NEP-1 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6wMlAy6oDVMUCuNEDPxE1? NX7sc29[OjRiaB?= M{XPWGROW00EoB?= M1XHeGlEPTB;N{[uN|Qhdk1? M2jU[FI3OTd4MkG5
G401 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKxNE4xOeLCk{GwMlAh|ryP MWGyOEBp MlOxSG1UV8Li NVfifpRHUUN3ME2xOFMvODJibl2= MkDkNlYyPzZ{MUm=
SK-NEP-1 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoTGOVAhdk1? MYCx5qCUPCCm M{S3bGROW00EoB?= NV;FVmM5emWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M{GzN|I3OTd4MkG5
G401 M{jRXmNmdGxiVnnhZoltcXS7IFHzd4F6 NYXJc5diPTBibl2= M2fyTFHjiJN2IHS= NWjQPGxPTE2VT9Mg MYry[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NVXWNHhyOjZzN{[yNVk>
SK-NEP-1 MnLWRZBweHSxc3nzJGF{e2G7 NXn3TGRUPTBxMUCwJI5O MWKyOEBp NIP1cYRFVVORwrC= M4joXolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVuyOlE4PjJzOR?=
G401 MUTBdI9xfG:|aYOgRZN{[Xl? NWjUS3hNPTBxMUCwJI5O M4O1SFI1KGh? NULpco1RTE2VT9Mg MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUSyOlE4PjJzOR?=
SK-NEP-1 NF;xdoVHfW6ldHnvckBCe3OjeR?= NVW2OHZ4PTBxMUCwJI5O NVjHe5R3OjRiaB?= MVjEUXNQyqB? MYHzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v NFzwU44zPjF5NkKxPS=>
G401 M2jNbGZ2dmO2aX;uJGF{e2G7 NWLHW4ZSPTBxMUCwJI5O MnmzNlQhcA>? MmHJSG1UV8Li Mmn1d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? M{TKdVI3OTd4MkG5
SK-NEP-1 MX7GeY5kfGmxbjDBd5NigQ>? NV7TRXNmPTBxMUCwJI5O NHXNUlMzPCCq M1zZSWROW00EoB?= MXvpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> MoDVNlYyPzZ{MUm=
G401 MXzGeY5kfGmxbjDBd5NigQ>? MV:1NE8yODBibl2= MWiyOEBp M1LxVWROW00EoB?= NVTUOI5TcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NEfz[WIzPjF5NkKxPS=>
RPMI 8226 M1OyTmNmdGxiU4Xyeol3[WxiQYPzZZk> NGHpUmkzNzRxNjDuUS=> NVr3XmdPPDkkgJno NHmyZ2FqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq M4fvdlI3ODByMkmy
OPM2 MkjPR4VtdCCVdYL2bZZidCCDc4PhfS=> MVmyM|QwPiCwTR?= NG[xPVg1QOLCiXi= MnO4bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MkTCNlYxODB{OUK=
U266 M3zMcmNmdGxiU4Xyeol3[WxiQYPzZZk> NFfMUFczNzRxNjDuUS=> NWnrOGlOPDkkgJno NXX0PXpScW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NW\S[I85OjZyMECyPVI>
H929 MoLnR4VtdCCVdYL2bZZidCCDc4PhfS=> Mm\kNk81NzZibl2= MoPYOFjjiImq M3m4Rolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MmqyNlYxODB{OUK=
RPMI 8226  M4G3NmFxd3C2b4Ppd{BCe3OjeR?= NVu2dolJPOLCiX7N M1XLcVI1NzR6IHi= MmXObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NI[wOWczPjByMEK5Ni=>
HCC827 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\4fZdSOTBibl2= NF\xV2Y1QCCq MmD6SG1UVw>? MnzC[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? NGqxTHgzPTl2NE[xOy=>
NCI-H23 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPZUFcyOCCwTR?= NEfNdII1QCCq MV\EUXNQ M3LIbYVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NH7EboMzPTl2NE[xOy=>
AML3 MXfGeY5kfGmxbjDBd5NigQ>? MofINE0yKM7:TR?= MWOyOOKhcA>? NITRWlNqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXeyOVYyOjl2MR?=
ML-1 NWLsVox2TnWwY4Tpc44hSXO|YYm= NI\zU2sxNTFizszN M3W0SlI1yqCq MXvpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2PwTlI2PjF{OUSx
RPMI-8226vr10  NX\iVpVTTnWwY4Tpc44hSXO|YYm= MXmwMVEh|ryP MmnNNlTDqGh? MWjpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{XlOlI2PjF{OUSx
ML-1 M1jQ[mZ2dmO2aX;uJGF{e2G7 Mom2NUDPxE1? Ml\nNlTDqGh? MmS5bY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= M3jlb|I2PjF{OUSx
RPMI-8226vr10  MkjKSpVv[3Srb36gRZN{[Xl? MojmNUDPxE1? Mly0NlTDqGh? NIqzd2FqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl M131NVI2PjF{OUSx
SK-N-BE (2) NGHvOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74U5RJOjUkgJno MmDoTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NFXGRnUzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK M1PEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPHc3hsOjUkgJno M3HHb2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MUmyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN M2KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jTZlI16oDLaB?= M3LPe2lEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NULqOYw4OjV|MEi5NVY>
SK-N-AS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuyOQKBkWh? MWXJR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? NV7Vd2s4OjV|MEi5NVY>
SK-N-DZ NYT5R49sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy1d5ozPOLCiXi= Ml\ZTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? MYqyOVMxQDlzNh?=
Caki-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH3NVAwOjVxNUCgcm0> NF[0OW81QCCq Mn3ZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MoS4NlUzPzlzOUG=
ACHN NIDnVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjToJrOTBxMkWvOVAhdk1? MVG0PEBp NGT5cXhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MlTxNlUzPzlzOUG=
769-P NUXhNWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPPNVAwOjVxNUCgcm0> Mm\2OFghcA>? NHfYXVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MXKyOVI4QTF7MR?=
786-O  NWPYbphwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNE8zPS93MDDuUS=> M1LLc|Q5KGh? NG[0cllqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MlX0NlUzPzlzOUG=
Caki-1 MlzkRZBweHSxc3nzJGF{e2G7 Moq4OVAhdk1? MVm0PEBp NGHzO|JqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M3PZPVI2Ojd7MUmx
ACHN M1voTGFxd3C2b4Ppd{BCe3OjeR?= MknTOVAhdk1? M4XhUVQ5KGh? MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NW\XNIdYOjV{N{mxPVE>
769-P MWXBdI9xfG:|aYOgRZN{[Xl? NWP3U5BoPTBibl2= MoXFOFghcA>? NEfNZmtqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NYPoeZZkOjV{N{mxPVE>
786-O  M2LvTGFxd3C2b4Ppd{BCe3OjeR?= M1[0fFUxKG6P NFf4Z|E1QCCq NV2xOGc1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= M2XLRlI2Ojd7MUmx
Caki-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[yOU82OCCwTR?= NVPsXWp7PDhiaB?= MkWySG1UVw>? NHXxeVNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MX2yOVE4PjN3NB?=
ACHN Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyyOU82OCCwTR?= NWTEVHJ{PDhiaB?= NXnsUoRETE2VTx?= NYi5[3VocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NUK4W|Z4OjVzN{[zOVQ>
769-P NIf0bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK3NlUwPTBibl2= NEHlZpM1QCCq NED6NYhFVVOR MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MVKyOVE4PjN3NB?=
Caki-1 NWDDdZNIS2:ub375JGZwem2jdHnvckBCe3OjeR?= NILuVpI2OCCwTR?= Mm\TO{0yPCCm MmiySG1UVw>? MmCyd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NGTybGIzPTF5NkO1OC=>
ACHN NHLN[XhEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MYK1NEBvVQ>? MoHGO{0yPCCm M3nBeGROW09? NEHDUWR{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MYCyOVE4PjN3NB?=
769-P NVvEVGo6S2:ub375JGZwem2jdHnvckBCe3OjeR?= NX[xVWhnPTBibl2= M2XhV|cuOTRiZB?= MmLTSG1UVw>? NH7l[G1{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MXuyOVE4PjN3NB?=
Caki-1 NYXiVG86SXCxcITvd4l{KEG|c3H5 M1nEXlUxKG6P MlfiOFghcA>? MoHMSG1UVw>? MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkjHNlUyPzZ|NUS=
ACHN M4LPcGFxd3C2b4Ppd{BCe3OjeR?= MlrnOVAhdk1? NVewOphXPDhiaB?= NIWzT4lFVVOR NU\KPYo{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUSyOVE4PjN3NB?=
769-P Mn3QRZBweHSxc3nzJGF{e2G7 NXH0RWQ3PTBibl2= M{HFeFQ5KGh? M1O1[WROW09? NH\tc3RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NV[0ZpFIOjVzN{[zOVQ>
MDA-MB-231 NVW2VI56VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 M3zEV|ExyqCwTR?= MWWzxsBl M3jBRmROW09? NFHpW2NidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= NIrzdoYzPDhzMES5Oy=>
BT-549 NEXtRpBOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? MnT4NVDDqG6P Mk\IN:Kh\A>? MVPEUXNQ NWDKW4dK[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MWWyOFgyODR7Nx?=
MCF-7  MYLNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> M1\rN|ExyqCwTR?= M1;2SFPDqGR? M12zZ2ROW09? M4OxcIFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NEfDTnUzPDhzMES5Oy=>
MCF-7 NYDOcmxxTnWwY4Tpc44hSXO|YYm= M1PmdlUuPTBibl2= MlrBNlQhcA>? MnO4SG1UVw>? NWnmN3dEemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? MUmyOFM3PjRyNx?=
CTS NH34W3pCeG:ydH;zbZMhSXO|YYm= MVOw5qCUPDBibl5CpC=> MVy0PEBp M2P2R4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4HVcFI1OjR2NEK5
OCI-AML3  MoXXRZBweHSxc3nzJGF{e2G7 MUGw5qCUPDBibl5CpC=> NV;RZ29zPDhiaB?= MnK0bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFyyXZgzPDJ2NESyPS=>
U937 Ml3KRZBweHSxc3nzJGF{e2G7 MkGzNQKBmzRyIH7NxsA> MkTtOFghcA>? M2LESIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1y3Z|I1OjR2NEK5
PC3 MVLBdI9xfG:|aYOgRZN{[Xl? NXTVc2Q3OC1zMECgcm0> M2\pdlI1NzR6IHi= NIjJN4NqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGf2bWkzPDF4M{KzNC=>
PC3-AR NYfzZY1QSXCxcITvd4l{KEG|c3H5 MoTtNE0yODBibl2= M2O4ZVI1NzR6IHi= NF;ocldqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYHyOXk5OjRzNkOyN|A>
PC3 M{\3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmUXl[OC1zMECgcm0> MWeyOE81QCCq Mkj5bY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? MknONlQyPjN{M{C=
PC3-AR NVjGTWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqwbld2OC1zMECgcm0> NEfFcWQzPC92ODDo M{DZ[4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= MWWyOFE3OzJ|MB?=
PC3 MVnGeY5kfGmxbjDBd5NigQ>? NIr0[2ExNTFyMDDuUS=> NFzVdVYzPCCq NHjubWJ{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> M13HOFI1OTZ|MkOw
PC3-AR NFrhPHpHfW6ldHnvckBCe3OjeR?= MVOwMVExOCCwTR?= NEfDcJUzPCCq NH\ROHZ{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> NFzWTHEzPDF4M{KzNC=>
OS-RC-2 MnHsR4VtdCCYaXHibYxqfHliQYPzZZk> NGXBZ3oxNTFyMECgcm0> MofKNlQwPDhxN{KgbC=> NYL5TYt[TE2VTx?= NH65WW1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MknYNlQyPDR5M{e=
OS-RC-2 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC1NEBvVQ>? MUS0PEBp NUfQZWE2TE2VTx?= NWHIbnBKcW6mdXPld{BIOi:PIHHydoV{fA>? M3zUfVI1OTR2N{O3
OS-RC-2 MXHBdI9xfG:|aYOgRZN{[Xl? MUe1NEBvVQ>? MXW0PEBp NUS5THl3TE2VTx?= MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFfZUYozPDF2NEezOy=>
SK-N-AS NFqz[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3NQKBmzhyIH7N NXfxSXN4PDhiaB?= NULrW2RzUUN3ME2yO{41KG6P NVrMcXhFOjRyOUi3PVk>
SK-N-DZ NI\BRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnvNQKBmzhyIH7N NXjFd2ZUPDhiaB?= NEX0UYFKSzVyPUKxMlkhdk1? MoPrNlQxQTh5OUm=
SK-N-SH Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUXHMx6oDVOECgcm0> Mn7DOFghcA>? MlnkTWM2OD15Mj6zJI5O NX3zO4xMOjRyOUi3PVk>
SK-N-BE NHvEVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPyNQKBmzhyIH7N NHz2WZY1QCCq MWLJR|UxRTd3LkSgcm0> MWOyOFA6QDd7OR?=
SK-N-AS NYX4RWhjSXCxcITvd4l{KEG|c3H5 NHPofncx6oDVOECgcm0> M37y[VQ5KGh? MnXhdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u M3zDdVI1ODl6N{m5
SK-N-DZ MWTBdI9xfG:|aYOgRZN{[Xl? MUew5qCUQDBibl2= NU\PNIxUPDhiaB?= NFGyenlxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M3m4bFI1ODl6N{m5
SK-N-SH Mne3RZBweHSxc3nzJGF{e2G7 NIXab|Ux6oDVNECgcm0> MYC0PEBp NG[5emNxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MnzQNlQxQTh5OUm=
SK-N-BE MoGxRZBweHSxc3nzJGF{e2G7 NUjzfZBUOOLCk{SwJI5O NWGxOZRrPDhiaB?= Mne3dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NVPVb5hCOjRyOUi3PVk>
SK-N-AS M1XtOmZ2dmO2aX;uJGF{e2G7 NHHyTnAx6oDVOECgcm0> Mn:0OFghcA>? NWDa[JlucW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MWWyOFA6QDd7OR?=
SK-N-DZ MUTGeY5kfGmxbjDBd5NigQ>? NFHtW24x6oDVOECgcm0> M{HpSVQ5KGh? MYTpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ Mlr4NlQxQTh5OUm=
SK-N-SH MXHGeY5kfGmxbjDBd5NigQ>? M2jYUFDjiJN2MDDuUS=> M4DwUlQ5KGh? M3fzXYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MoTENlQxQTh5OUm=
SK-N-BE MWfGeY5kfGmxbjDBd5NigQ>? MXuw5qCUPDBibl2= NWnYOnFsPDhiaB?= MWLpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MkDGNlQxQTh5OUm=
HCC-LM3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxMVExODBibl2= M160PVI1NzR6L{eyJIg> M{HSSWROW09? NUXkPYdbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGGzcZAzPDB7M{m1Oi=>
HepG2 NY\XbVJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O0dVEuOTByMDDuUS=> MYGyOE81QC95MjDo MWnEUXNQ M{[1R4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NG\m[oEzPDB7M{m1Oi=>
SMMC-7721 NHi1S|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HuVVEuOTByMDDuUS=> Mmr3NlQwPDhxN{KgbC=> MnniSG1UVw>? M3;SNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXWyOFA6Ozl3Nh?=
HCC-LM3 NX\OSWNpSXCxcITvd4l{KEG|c3H5 MoXJOVAhdk1? MVm0PEBp NEDPcHdFVVOR NUfTdFVGcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? M33oeFI1ODl|OUW2
HepG2 MoTURZBweHSxc3nzJGF{e2G7 M3rQ[|UxKG6P NX\YW2VyPDhiaB?= MofaSG1UVw>? NF70cVFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M1\1S|I1ODl|OUW2
SMMC-7721 Mn:yRZBweHSxc3nzJGF{e2G7 NV23fYhFPTBibl2= NUj5bXJOPDhiaB?= MYnEUXNQ MVPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NHzzVnUzPDB7M{m1Oi=>
HCC-LM3 M2TIOGZ2dmO2aX;uJGF{e2G7 NGHTToc2OC9zMECgcm0> MXKyOEBp MnfESG1UVw>? NFnlfVll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NIXSeGwzPDB7M{m1Oi=>
HepG2 M4r6SGZ2dmO2aX;uJGF{e2G7 MXW1NE8yODBibl2= MmnuNlQhcA>? MXHEUXNQ M4PlR4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MUCyOFA6Ozl3Nh?=
SMMC-7721 M1PvNmZ2dmO2aX;uJGF{e2G7 MmDvOVAwOTByIH7N NWflWHpsOjRiaB?= NUi2RYVVTE2VTx?= NFnqXZBl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NVy4clJHOjRyOUO5OVY>
HCC-LM3 NFr4RplHfW6ldHnvckBCe3OjeR?= NUXlbm5iPTBxMUCwJI5O M2ixcFI1KGh? MlvESG1UVw>? NX3hclhm\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= M1\vcVI1ODl|OUW2
HepG2 NHHrXlJHfW6ldHnvckBCe3OjeR?= M2r5Z|UxNzFyMDDuUS=> MY[yOEBp NVPyT2xiTE2VTx?= MnX0[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MWOyOFA6Ozl3Nh?=
SMMC-7721 MlfZSpVv[3Srb36gRZN{[Xl? MYq1NE8yODBibl2= NH\iNJQzPCCq MWnEUXNQ MUXkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v M{TJXFI1ODl|OUW2
FaDu M3;lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTVNVAx6oDHbl2= MlLLPE8yOC9zMjDo MWTkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? MW[yOFAzPjR6Mh?=
FaDu NEixdG5HfW6ldHnvckBCe3OjeR?= MXqxNFDjiIWwTR?= MnrwNk81NzhxMUKgbC=> NVvLfW9QcW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36= NHq2dW4zPDB{NkS4Ni=>
PC-3  NVLQfYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnOU5BNOC1zMDFOwG0> MWmyOE81QC95MjDo MnyxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnjjNlM6QTF{MU[=
LNCaP NHzI[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3yNlRmOC13IN88US=> NV;obGs{OjRxNEivO|IhcA>? NXPJfnBocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUOyN|k6OTJzNh?=
RWPE-1  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmxZ|MxNTJyIN88US=> MmDjNlQwPDhxN{KgbC=> MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUKyN|k6OTJzNh?=
Capan-1 NXrwTFNwTnWwY4Tpc44hSXO|YYm= MnPlNlUwPTBxMUCwJI5O NV:1VZdyQC9{ND:0PEBp NG\DTXRFVVOR NVXFellV\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> Mle2NlM6OjJ6OE[=
L3.6pl MX3GeY5kfGmxbjDBd5NigQ>? MoTCNlUwPTBxMUCwJI5O MWS4M|I1NzR6IHi= Mo\pSG1UVw>? Ml;h[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MWmyN|kzOjh6Nh?=
CFPAC-1  M3XBe2Z2dmO2aX;uJGF{e2G7 NEm2N4EzPS93MD:xNFAhdk1? NUfrVllPQC9{ND:0PEBp M1jvOmROW09? MYDkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MWqyN|kzOjh6Nh?=
Capan-1 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLROnEzPS93MD:xNFAhdk1? Mo\mOFghcA>? NGPKXZRFVVOR NHfrWYZz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NES5NXUzOzl{Mki4Oi=>
L3.6pl Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7INlUwPTBxMUCwJI5O NVzy[Fl{PDhiaB?= NX7qdVd2TE2VTx?= MoHxdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEXjdpAzOzl{Mki4Oi=>
CFPAC-1  M4Hmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjqeHhvOjVxNUCvNVAxKG6P MVm0PEBp NYPkc4tSTE2VTx?= NGfmV3Rz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnXnNlM6OjJ6OE[=
Capan-1 NGDzb3BCeG:ydH;zbZMhSXO|YYm= NH\je3gzPS93MD:xNFAhdk1? MW[0PEBp NFm4TZFFVVOR MXzpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYT1TmFoOjN7MkK4PFY>
L3.6pl MoDrRZBweHSxc3nzJGF{e2G7 MYCyOU82OC9zMECgcm0> NYfpT41iPDhiaB?= MXXEUXNQ NI\kUpZqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnzPNlM6OjJ6OE[=
CFPAC-1  MV;BdI9xfG:|aYOgRZN{[Xl? M2\VXlI2NzVyL{GwNEBvVQ>? MmrPOFghcA>? M4K3XWROW09? MnHXbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1HocVI{QTJ{OEi2
HN22 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELxW4gxNTJyIH7N MlL2NlQwPDhiaB?= MX\EUXNQ Mn:1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NGnTOlkzOzh5N{KzOS=>
HSC4  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInEeIIxNTJyIH7N MWWyOE81QCCq NV;KPFZUTE2VTx?= NHL6RYpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M4fEelI{QDd5MkO1
HN22 MV7BdI9xfG:|aYOgRZN{[Xl? MUGwMVIxKG6P MnfxOFghcA>? NIjSXpVFVVOR MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVWyN|g4PzJ|NR?=
HSC4  NXXwOI1OSXCxcITvd4l{KEG|c3H5 MXywMVIxKG6P NEHlW4E1QCCq MWLEUXNQ MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{nKelI{QDd5MkO1
HN22 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DPSFAuOjBibl2= MlrTOFghcA>? NHrzdW5FVVOR M2noSYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> M1fMe|I{QDd5MkO1
HSC4  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVIxKG6P Moi5OFghcA>? M1fkeWROW09? MmfpbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg M4DuUVI{QDd5MkO1
HN22 MmHjSpVv[3Srb36gRZN{[Xl? NHzFbncxNTJyIH7N MnzZOFghcA>? NFf4bGxFVVOR MUnzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= M2fZUFI{QDd5MkO1
HSC4  MYPGeY5kfGmxbjDBd5NigQ>? NXnOWG84OC1{MDDuUS=> NHnkenE1QCCq NUHVNmtyTE2VTx?= M4LrbZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> NVfhT3lNOjN6N{eyN|U>
Cal62 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H5bWlEPTB;M{OgxtEhPCCwTR?= NHyxR2YzOzh{NEC2OC=>
Hth7 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\PTWM2OD1zNTFCtUAzKG6P NGTydFQzOzh{NEC2OC=>
Hth83 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPQTWM2OD1|NDFCtUA2KG6P Ml7TNlM5OjRyNkS=
C643 NUfpfpRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdzINMxJFExKG6P NV7Wb|RIOjN6MkSwOlQ>
SW1736 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTEUWJHUUN3ME2zOUDDuSB6IH7N M1\GSVI{QDJ2ME[0
T241 NUCzPWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf6XVZKSzVyPU[1JOKyKDdibl2= M4DTc|I{QDJ2ME[0
T351 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTVyINMxJFExKG6P M4nYUlI{QDJ2ME[0
BHP2-7 M3vhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXmTWM2OD1|NzFCtUA3KG6P NUe1V5c{OjN6MkSwOlQ>
T238 M3u0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYiyWJFXUUN3ME2xMFUxOCEEsTCyNFAhdk1? Ml3vNlM5OjRyNkS=
HCT8 M4S2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nGc|czKGh? M{mxRmROW09? NHfzV2NKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= M1fvUFI{Ojl7M{i4
H630 NGi0eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrjT2lrPzJiaB?= MnnjSG1UVw>? NXm3PY04UUN3ME2xNk416oDLwsJihKk{NjFibl2= NIixZnczOzJ7OUO4PC=>
cH630 5-FU-res MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzJ[|A4OiCq NF;FXpFFVVOR MlrTTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? MlzKNlMzQTl|OEi=
HCT116 NXLpZWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3BV2YyPzJiaB?= MnHwSG1UVw>? MmLyTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? M4SzcVI{Ojl7M{i4
HCT116 p53−/− NIruOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuO|IhcA>? NWTyd2k3TE2VTx?= MojoTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? NHLUUYszOzJ7OUO4PC=>
dHCT116 p21−/− M3HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnkd5A4OiCq MXvEUXNQ Mk[3TWM2OD13LkpihKnDueLCiUGuN{BvVQ>? NEHiXG0zOzJ7OUO4PC=>
HT29 M1r4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PVdVczKGh? MUXEUXNQ MWfJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? M4fEU|I{Ojl7M{i4
LoVo Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3NkBp M37VWmROW09? Ml\oTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? MkHKNlMzQTl|OEi=
RKO M3fxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:2T|czKGh? MoW3SG1UVw>? M{HCU2lEPTB;Nz655qCKyrIkgJmyMlIhdk1? NXnXNXhvOjN{OUmzPFg>
SW480 NXLLTIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjt[Io4OiCq MknFSG1UVw>? NVLXRYxsUUN3ME2xO{426oDLwsJihKkxNjhibl2= NUf3[41ZOjN{OUmzPFg>
eSW620 NYD3dZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rXbVczKGh? NHfyNYNFVVOR NULYdpRCUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= NET0O2MzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID